Leerink Partners Maintains Johnson & Johnson(JNJ.US) With Buy Rating
Morgan Stanley Maintains Johnson & Johnson(JNJ.US) With Hold Rating, Maintains Target Price $169
Cantor Fitzgerald Reiterates Overweight on Johnson & Johnson, Maintains $215 Price Target
Johnson & Johnson Analyst Ratings
Cantor Fitzgerald Maintains Johnson & Johnson(JNJ.US) With Buy Rating, Maintains Target Price $215
Johnson & Johnson Analyst Ratings
RBC Capital Maintains Johnson & Johnson(JNJ.US) With Buy Rating, Maintains Target Price $175
Johnson & Johnson Analyst Ratings
Daiwa Downgrades Johnson & Johnson to Neutral From Outperform, Adjusts Price Target to $150 From $160
Guggenheim Adjusts Johnson & Johnson's Price Target to $156 From $160, Maintains Neutral Rating
Buy Rating Affirmed for Johnson & Johnson on Strong Growth and Strategic Acquisitions
Johnson & Johnson Analyst Ratings
HSBC Adjusts Price Target on Johnson & Johnson to $174 From $170, Maintains Buy Rating
RBC Capital Reiterates Outperform on Johnson & Johnson, Maintains $175 Price Target
Johnson & Johnson (JNJ) Gets a Buy From RBC Capital
Morgan Stanley Adjusts Price Target on Johnson & Johnson to $169 From $167, Maintains Equalweight Rating
Johnson & Johnson Analyst Ratings
Stifel Raises Johnson & Johnson's Price Target to $160 From $155
Hold Rating Maintained Amid Johnson & Johnson Acquisition and Foreign Exchange Concerns
Stifel Nicolaus Remains a Hold on Johnson & Johnson (JNJ)